TFAP2 suppresses tumor proliferation mediated through P21 (also known as CDKN1A, cyclin dependent kinase inhibitor 1A) regulation in several types of tumors, such as melanoma, breast cancer, colorectal cancer, pancreatic cancer and neuroblastoma [12, 83–89]. Here, CDKN1A is linked to breast carcinoma.